Wednesday, January 9, 2013

Verisome wins FDA's orphan drug designation

This week, the preclinial eye injection compound created by Icon Bioscience to treat a form of childhood eye cancer won the FDA orphan drug design. The chemotherapy drug will be paired with Icon's drug delivery system, which will administer the medication through the eye and release it at a slower pace.

With the orphan designation, the FDA incentivizes the development of treatments for rare diseases--the designation grants benefits such as tax breaks, fee waivers and market exclusivity to offset the effect of a smaller patient population.

The current form of chemotherapy that is most commonly used is administered through a catheter via the groin and into the eye. The delivery device created by Icon, Verisome, will also make it easier for doctors to monitor the patient throughout treatment.Verisome is also used for treating inflammation post eye surgery for various procedures such as cataract surgery, glaucoma, uveitis, and many others. What other types of procedures could Verisome be used for?

The expectations of regulatory systems continue to change, so how do you keep up? Attend our full day symposium : Maximize the Potential of Your Drug Delivery System through Drug Delivery Device Combination Products at the 17th annual Drug Delivery Partnerships. To learn more about the sessions offered at this years event, download our brochure.

As a reader of the Drug Delivery Partnerships blog, you get a 15% discount off the standard rate when using code XP1878BLOG to register. We look forward to seeing you February 6-8 in San Diego, CA!

No comments:

Post a Comment